Winstrol (Stanozolol) is an Anabolic Steroid that was derived from Testosterone in 1962 by Winthrop Labs . The original purpose of this steroid was to help treat people suffering from anemia, it is also often used for veterinary purposes. This high anabolic, low androgenic steroid does not bind to the androgen receptor. For this reason Winstrol is considered a weak steroid in terms of its muscle building properties, it does however cause great increases in strength. Stanozolol is also a popular steroid for females due to its low androgenic properties it makes it a safer choice as side effects such as voice deepening and facial hair are a lower risk when compared to steroids such as Dianabol . This doesn’t mean females should use Winstrol as irreversible masculine side effects are still a risk.
LABORATORY CONTROL: The PT reflects the depression of vitamin K dependent Factors VII, X and II. A system of standardizing the PT in oral anticoagulant control was introduced by the World Health Organization in 1983. It is based upon the determination of an International Normalized Ratio (INR) which provides a common basis for communication of PT results and interpretations of therapeutic ranges. 17 The PT should be determined daily after the administration of the initial dose until PT/INR results stabilize in the therapeutic range. Intervals between subsequent PT/INR determinations should be based upon the physician's judgment of the patient's reliability and response to Jantoven (warfarin sodium tablets) ® Tablets in order to maintain the individual within the therapeutic range. Acceptable intervals for PT/INR determinations are normally within the range of one to four weeks after a stable dosage has been determined. To ensure adequate control, it is recommended that additional PT tests be done when other warfarin products are interchanged with warfarin sodium tablets, USP, as well as whenever other medications are initiated, discontinued, or taken irregularly (see PRECAUTIONS ). Safety and efficacy of warfarin therapy can be improved by increasing the quality of laboratory control. Reports suggest that in usual care monitoring, patients are in therapeutic range only 33%-64% of the time. Time in therapeutic range is significantly greater (56%-93%) in patients managed by anticoagulation clinics, among self-testing and self-monitoring patients, and in patients managed with the help of computer Self-testing patients had fewer bleeding events than patients in usual care. 18